A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy

Endocrine. 2021 Oct;74(1):5-10. doi: 10.1007/s12020-021-02763-5. Epub 2021 May 27.

Abstract

Purpose: Familial hyperaldosteronism type 1 (FH-1) is a rare autosomal dominant form of primary aldosteronism, which features a marked phenotypic heterogeneity, ranging from mild to severe forms of arterial hypertension that can be complicated by stroke and cardiovascular events at a young age. As affected patients usually reach the fertile age, transmission of the disease to offspring is common. Notwithstanding this, reports of FH-1 in pregnancy are limited and there is a lack of treatment guidelines.

Methods and results: We searched the PubMed and EuropePMC databases with a PICO strategy to retrieve available information on management of FH-1 patients during pregnancy. We could identify seven relevant articles, which are herein reviewed.

Conclusion: Based on available information on pathophysiology and treatment of FH-1 in pregnancy, recommendations for the rational management of FH-1 in pregnancy are provided.

Keywords: Familial Hyperaldosteronism type 1; Glucocorticoid-remediable aldosteronism; Hypertension; Pregnancy; Primary Hyperaldosteronism.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Female
  • Humans
  • Hyperaldosteronism* / genetics
  • Hyperaldosteronism* / therapy
  • Hypertension*
  • Pregnancy
  • Stroke*

Supplementary concepts

  • Familial Hyperaldosteronism